(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
Revenue rose 48% to $23bn, driven mainly by Mounjaro and Zepbound volume, Lilly said. Second-quarter earnings per share ticked up 26% to $7.94 on a reported basis and...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE